A retrospective study of first‐line therapy and subsequent pyrotinib treatment in advanced lung adenocarcinoma with HER2 mutations

Ähnliche Einträge

• Prognostic impact of the timing of immunotherapy in first‐line immunochemotherapy for patients with advanced lung adenocarcinoma: A propensity score‐matched analysis
  von: Yanxin Sun, et al.
  Veröffentlicht: (2025)
• Major advancements in first‐line treatments for advanced urothelial cancer
  von: Mary Beth Nierengarten
  Veröffentlicht: (2024)
• Efficacy of ramucirumab combination chemotherapy as second‐line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first‐line therapy
  von: Michael Masetti, et al.
  Veröffentlicht: (2024)
• HER2 mutation as an emerging target in advanced breast cancer
  von: Giulia Bon, et al.
  Veröffentlicht: (2024)
• Clinical relevance of somatic mutations in Chinese lung adenocarcinoma and their prognostic implications for survival
  von: Tongxin Li, et al.
  Veröffentlicht: (2024)